drugset / Trial / NCT02187198

Buprenorphine Treatment for Opioid Dependence

NCT02187198

RandomizedParallel-groupOpen-labelTreatment

Summary

Buprenorphine/naloxone (BUP/NLX) treatment is effective for the treatment of prescription opioid dependence, previous studies have not determined the optimum dose of BUP/NLX for this patient population. The goal of this study is to determine if there are differences in clinical efficacy of BUP/NLX tablet in low dose range (less than or equal to 8/2mg) vs. high dose range (greater than or equal to 16, range 16-24mg). The main outcomes of interest will be treatment retention, use of opioids, and the use of other drugs of abuse.

Timeline

Start
2015-03
Primary completion
2022-02-01
Completion
2023-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 8 mg
Subject Buprenorphine Other / unclassified 16 mg
Subject Buprenorphine Other / unclassified 24 mg

Indications